Raffaele Colombo, Director of Medicinal Chemistry at Zymeworks Inc., shared a post on LinkedIn:
“With the AACR26 Annual Meeting week winding down, it is time to some reflections.
Giving a plenary at AACR is something I could only dream of. Thank you American Association for Cancer Research for the trust and the opportunity to contribute to such an outstanding program. What stands out even more are the people. Over the years, AACR has come to feel like family!
Even more proud of the Zymeworks Inc. ADC team for presenting 6 posters! Our novel RASi platform for ADCs and RASi ADC programs (ZW427, ZW418, ZW439), the development of mRNA translation inhibitors for ADCs, and ZW191 preclinical combination work presented by Graham Garnett, Mark Petersen, Dunja Urosev, Ambroise Wu, Vincent Fung, and Samuel Lawn at AACR26 are the results of a truly collective and multidisciplinary effort to expand beyond traditional ADCs.
Also, I’m very excited about our latest manuscript published in Annals of Oncology, published just one day before my talk (perfect timing!). This paper represents many nights and weekends of work over several months and many many many discussions with a lot of people, but particularly with Jamie Rich. And of course Stuart Barnscher and Steve Seredick.
Enjoy it!
Finally, earlier this year I was promoted to Director, Medicinal Chemistry. I had been meaning to share the news, but with everything else going on I never quite found the right moment. I’m very grateful to Zymeworks leadership, colleagues, and collaborators for their support and mentorship, and above all for their friendship.
Looking forward to building on this momentum: strong science, meaningful connections, and a clear goal of making an impact for patients.”
More posts featuring Raffaele Colombo.
